Novartis Medical’s Post

👉 Conference Alert! I will be happy to meet you at #ADLM and talk about how you can use our solutions in your lab!

My colleagues, Jim Adair & Matt Alsante, wrote an article on how patients are at the forefront of scientific innovation at BMS, and how our colleagues share a goal of improving the lives of patients with blood cancers around the world. Read the latest #DecodedByBMS article to learn more about why this patient centric approach is fundamental in our commitment to hematology. #BloodCancerAwarenessMonth #BMS_Employee

Back in December, Dr. Oussama Abla presented his study of: "Langerhans cell histiocytosis: promises and caveats of targeted therapies in high-risk and CNS disease" at the American Society of Hematology Annual Meeting In the video Deanna sat down with him to review the key takeaways from the study, what the challenges are, and how it can take us forward. View the video here: https://lnkd.in/e8JGdGz9

IACH News of the week 14.7.24 We share this week's summaries: International Academy for Clinical Hematology (IACH) Mohamad Mohty -cHL: BrECADD vs. eBEACOPP - Glucarpidase & outpte. HD-MTX treat. for CNS lymphoma - Mitral regurg. & VW disease - NRM pos-CAR T-cell therapy - Differentiation in AML: How I Treat

🌐 Happy to share the Most Viewed Special Issues in 2023 in the Section “Cancer Drug Development” in Cancers MDPI MDPI❕  The Special Issues list is as follows↘️ https://lnkd.in/dK8r5pJR

Seemingly daily update on secondary cancers post CAR T. FDA (Nicole Verdun and Peter Marks) published a paper in NEJM with more information about the investigation. TLDR: *5/6 approved CAR T had patients develop a secondary malignancy *22 cases out of >27,000 doses *Secondary malignancies occurred between 1-19 months post infusion *In 3 cases, the CAR transgene was found in the malignant clone suggesting the CAR was associated with the cancer https://lnkd.in/enKx2xQF

Czech clinical trials lead with 40% increase in cancer drug studies "The decision to participate in a clinical trial must be truly the patient's own. We, as doctors, offer the study when we believe it's suitable for the patient. However, we must clearly explain what participation entails, the associated risks, and the potential benefits without promising a favourable outcome," said Jan Vydra, head of the clinical department at the Czech Institute of Haematology and Blood Transfusion. "If the Czech Republic wants to remain on the clinical trial map, systematic support for the research environment is essential. Strengthening clinical trial departments and reducing administrative burdens through digitalisation are critical steps," Kolář emphasised. The analysis presented by Czech AIFP also pointed out that this year, the total number of clinical trials in Europe reached 140,300, which is a 20% increase compared to 2022. https://lnkd.in/ejp6rbCn #PublicHealth #Europe #StayInformed #StayEmpowered

Shifting gears: CAR-T therapy, renowned for cancer treatment, is now revealing promising responses in autoimmune diseases. This breakthrough opens new possibilities for innovative treatments beyond cancer. #MedicalAdvancements #CAR-T https://lnkd.in/e8_GGS6x